Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Accured Expenses: 2019-2025

Historic Change in Accured Expenses for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $26.4 million.

  • BridgeBio Pharma's Change in Accured Expenses rose 1396.09% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.6 million, marking a year-over-year increase of 1333.37%. This contributed to the annual value of $17.0 million for FY2024, which is 117.71% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Change in Accured Expenses of $26.4 million as of Q3 2025, which was down 42.53% from $46.0 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Change in Accured Expenses ranged from a high of $46.0 million in Q2 2025 and a low of -$19.4 million during Q1 2025.
  • In the last 3 years, BridgeBio Pharma's Change in Accured Expenses had a median value of $6.9 million in 2023 and averaged $7.1 million.
  • In the last 5 years, BridgeBio Pharma's Change in Accured Expenses plummeted by 93.09% in 2022 and then surged by 2,369.64% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Change in Accured Expenses (Quarterly) stood at $18.6 million in 2021, then tumbled by 92.51% to $1.4 million in 2022, then surged by 758.44% to $12.0 million in 2023, then surged by 97.34% to $23.6 million in 2024, then soared by 1,396.09% to $26.4 million in 2025.
  • Its Change in Accured Expenses stands at $26.4 million for Q3 2025, versus $46.0 million for Q2 2025 and -$19.4 million for Q1 2025.